Nexvet Biopharma (NVET) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Nexvet Biopharma (NVET) Tops Q1 EPS by 4c
May 8, 2015 5:30 AM EDT
DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three and nine month periods ended March 31, 2015.
Corporate Highlights
In February 2015, we closed our initial public offering of 4.0 million ordinary shares at a price to the public of $10.00 per share. The underwriters partially exercised their over-allotment option and purchased an additional 0.2 million shares. Following the sales of these securities, we received aggregate gross proceeds of $41.8 million and net proceeds of $38.0 million.
Â
In March...
More
May 8, 2015 5:30 AM EDT
DUBLIN, Ireland and MELBOURNE, Australia, May 8, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq: NVET) today announced its financial results for the three and nine month periods ended March 31, 2015.
Corporate Highlights
In February 2015, we closed our initial public offering of 4.0 million ordinary shares at a price to the public of $10.00 per share. The underwriters partially exercised their over-allotment option and purchased an additional 0.2 million shares. Following the sales of these securities, we received aggregate gross proceeds of $41.8 million and net proceeds of $38.0 million.
Â
In March...
More
May 7, 2015 5:30 AM EDT
DUBLIN, Ireland and MELBOURNE, Australia, May 7, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq: NVET), a veterinary biologic therapy developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas on Thursday, May 14, 2015 at... More
